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Abstract
The sarcoplasmic reticulum is an internal membrane system that controls the Ca2+
concentration inside muscle cells, and hence the contractile state of both skeletal and
cardiac muscle. A key protein that that regulates the Ca2+ concentration in this
membrane is known as the calcium release channel (CRC). The effects on Ca2+
dependent activation is of major importance in the study of CRC since other channel
modifiers cannot effect the channel in the absence of Ca2+, or they require Ca2+ for
maximum results. In this study of the high-affinity Ca2+ binding site, expected
increases in total binding and shifts in the sensitivity of the channel to Ca2+ were
observed when the pH increased or the solution redox status became more oxidative.
Ranolazine, a drug used for treating Angina Pectoris (chest pain), desensitized the
cardiac CRC activation but had no effect on the skeletal CRC. This selective
desensitization may be the cause of Ranolazine’s beneficial therapeutic effects. Both
Ranolazine, and homocystein thiolactone (HCTL), a naturally occurring derivative of
homocysteine, alters Ca2+ dependent activation by calcium without changing the
number of channels found in the open state. Surprisingly the effect of HCTL was
observed only in a reduced redox potential which leads to speculation that the
formation of an alpha-carbon radical by HCTL on the cardiac CRC only occurs if
select thiols are in a reduced state.
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Chapter 1: Introduction

1.1 The contraction of a muscle cell
Vertebrate muscle provides mechanical force upon stimulation and can be separated
into three types; skeletal, cardiac and smooth. In muscle cells, filaments called
myofibrils are surrounded by the sarcoplasmic reticulum (SR
(SR),
), a net like membrane
that is periodically penetrated by the transverse tubular system (T
(T-tubules)
tubules)1 at intervals
of approximately 1.2µm in skeletal muscle fibers and 2.5µm in cardiac ventricles. The
initiation of contraction is provided by an electrical eexcitation
xcitation called an action
potential that travels along the surface membrane of the muscle cell and down the TT
tubules allowing the action potential to travel across the surface of the entire muscle
fiber rapidly. The time that it takes skeletal muscle to contract is approximately 2-5ms,
2
where as cardiac muscle is slightly slower taking 20
20-50ms.

Figure 1: The sarcoplasmic reticulum and transverse tubule system of
striated muscle cells2.
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T-tubules are separated from the terminal cisternae3 of the SR by approximately 10nm
and the interaction between them is referred to as excitation-contraction coupling
(ECC). In this process three things must happen; the detection of the propagation of an
action potential along the T-tubules, the transmission of the information by the
dihydrophridine receptor (DHPR) to the Calcium Release Channel (CRC), and finally
the release of calcium from the SR. Figure 2 shows a schematic of the flow of calcium
out of the SR through the CRC where it binds to troponin at micromolar
concentrations, initiating contraction. After calcium is released from the SR, the Ca2+Mg2+-ATPase (Ca2+ pump) a 110kDa protein, pumps the calcium back into the lumen
of the SR causing the muscle to relax.

Figure 2: Excitation-contraction model4
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One of the major differences between cardiac and skeletal muscle is that ECC in
cardiac muscle requires a small amount of Ca2+ to cross the T-tubule, whereas in
skeletal muscle ECC is independent of the extracellular calcium5. The activation of the
CRC by calcium in cardiac muscle proceeds by a mechanism known as calcium
induced calcium release.6

1.2 Impact of abnormal Intracellular Ca2+ cycling
Problems with intracellular Ca2+ cycling have been associated with heart failure,
ischemic heart disease, and in several genetic forms of arrhythmias7. Heart failure is
characterized by abnormal intracellular Ca2+ cycling that leads to progressive
deterioration of cardiac function. Associated with heart failure is the inability of the
SR to build up an adequate Ca2+ load required for generating contraction, due to an
increased Ca2+ leak associated with the RyR2 channel. In cardiac muscle there are
additional proteins not found in skeletal muscle. Since Ca2+ enters the cell through the
DHPR to initiate cardiac muscle contraction there must be a mechanism of purging
Ca2+ from the cell. The Na+/ Ca2+ exchange protein (NCX) moves three Na+ ions into
the cell and one Ca2+ ion out of the cell. This is the primary mechanism for maintain
low intracellular Ca2+ concentrations in spite of the fact that Ca2+ enters the cell on
each beat of the heart. An abnormal Ca2+ leak from the SR during the relaxation phase
of the heart, when the cytosolic Ca2+ concentrations should be low, have been shown
to cause arrhythmias known as delayed afterdepolarizations (DADs)8. When
intracellular Ca2+ levels rise the NCX assists in removing the Ca2+ from the cell, which
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results in the influx of sodium and can lead to a depolarization of the extracellular
membrane. This unsynchronized action potential can generate arrhythmias. CRCs that
have a diastolic Ca2+ leak have consequently become a therapeutic target.

1.3 Calcium Release Channel
The calcium release channel is a cation selective trans membrane protein that is
thought to be a homotetramer with each of its subunits having a molecular weight of
about 565kDa. These subunits are arranged in a quatrefoil shape, 22 to 27nm on each
side with a 2nm hole in the center9. The plant alkaloid ryanodine binds to this protein
with high affinity and high selectivity when the channel is in its open state10. Because
of this, the channel is commonly referred to as the ryanodine receptor (RyR). The RyR
has three isoforms known as RyR1, RyR2 and RyR3. All three isoforms appear in
brain tissue, however RyR1 is found predominately in skeletal muscle, while RyR2 is
found primarily in cardiac muscle.

Figure 3: 3D reconstruction of the calcium release channel protein
(commonly known as the ryanodine receptor).11
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1.4 Modification of Ca2+ Release
Ca2+ has a biphasic role in the regulation of Ca2+ release. Low micromolar
concentrations stimulate the channel while high concentrations (>1mM) inhibit the
channel. This bell shaped Ca2+ dependence curve has been hypothesized to result from
two different binding sites, a high affinity site that opens the channel and a low
affinity site that inhibits release.12 While a rise in the Ca2+ concentration in the cytosol
is the principal factor stimulating the CRC13 in cardiac muscle, in skeletal muscle,
where ECC is independent of extracellular Ca2+ another mechanism of information
transfer must be present. It is generally believed that there is some type of
conformational coupling between the DHPR and the Ryanodine Receptor in skeletal
muscle but the precise mechanism is unknown.

There is direct evidence, however, for the existence, location and function of
hyperreactive thiols which have been reported in both skeletal14 and cardiac muscle15.
Figure 4 shows a proposed model of the Ca2+ release channel that is regulated by
several classes of sulfhydryl groups existing in close proximity and able to form
mixed disulfides. Oxidation of these hyperreactive sulfhydryl groups to a disulfide
linkage which opens the channel (S1-S2), is then followed by thiol-disulfide exchange
(S2-S3) that closes the channel, and finally, reduction of the disulfide bond by the
cellular oxidoreductive (redox) environment which resets the redox status. In support
of this model, it has been shown that the CRC has a well defined reduction potential
that is sensitive to the cellular environment.16 Channel activators lower the redox
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potential, making the value more negative, which favors the oxidation of thiols and the
opening of the channel, while channel inhibitors increase the redox potential to more
positive values, which favors the reduction of disulfides and the closure of the channel.
During oxidative stress or ischemia, these hyperreactive thiols could oxidize and alter
the Ca2+ sensitivity of the CRC allowing small changes in the calcium concentrations
to contribute to significant activation and release of Ca2+.

Figure 4: Model of the Ca2+ release protein gated by SH oxidation
and reduction of three endogenous SH groups.17
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Glutathione (GSH) is part of an antioxidant system and plays an important part in
maintaining the cellular redox status. It shares the job of scavenging peroxide, singlet
oxygen and other free radicals, with antioxidant vitamins and antioxidant enzymes,
and is the most abundant nonprotein thiol source in the muscle cell18. The eye lens has
the highest GSH concentrations at ~10mM, whereas muscle has about 1-2mM19.
During excessive production of reactive oxygen species (ROS) GSH donates a pair of
electrons to a hydroperoxide, resulting in 2 GSH being oxidized to 1 glutathione
disulfide (GSSG). The GSSG can then be reduced back to GSH by NADPH, which is
catalyzed by glutathione reductase (GR). When production of the ROS overwhelms
the recycling capacity of the GR, GSSG levels rise, resulting in a decrease of the
GSH/GSSG ratio and a more oxidized environment. While GSSG by itself is a
activator of the channel, and GSH is a known inhibitor it has been reported that ratio
of GSH/GSSG rather than the total GSH or total GSSG concentrations determine the
response of the RyR20. The typical mammalian cell ratio of [GSH]/[GSSG] in the
cytosol is ≥30:1 resulting in a reduction potential of approximately -230mV21. Transmembrane redox potential differences are on the order of 50mV with the lumen of the
SR being more oxidized than the cytosol30.

1.5 Regulation of the calcium dependence of the CRC by [H+]
During myocardial ischemia, when the flow of oxygenated blood to the myocardium is
diminished, the cellular pH can fall to as low as pH5.822. This condition, called
acidosis, has been shown to reduce the open probability of the isolated CRC
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incorporated into lipid bilayers23 which produces an increase in SR Ca2+ content, and
is also likely to decrease cytoplasmic Ca2+ buffering since Ca2+ and H+ ions share
common binding sites within both the skeletal and cardiac cell24. Therefore the pH
dependent inhibition of the CRC likely influences the physiological mechanism of
calcium induced calcium release.

1.6 Studied Compound - Ranolazine
The drug Ranolazine was approved for the treatment of Angina Pectoris (chest pain)
and ischemic heart disease in 1996 by the FDA. While Ranolazine at micromolar
concentrations is beneficial, it has been shown that it interacts with various ion
channels and metabolic pathways leaving the exact mechanism of the useful effects in
question. It is proposed that the beneficial effect of Ranolazine is due to a decrease in
a spontaneous Ca2+ leak across the SR membrane, not the previously proposed shifting
of myocardial energy metabolism from fatty acid to glucose oxidation25.

Figure 5: (RS)-N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide26

1.7 Studied Compound - Homocysteine Thiolactone
It has been established that increases in homocysteine levels is a risk factor for
cardiovascular disease and stroke in humans27. The thioester Homocysteine
Thiolactone (HCTL) is one of many metabolites of Homocysteine. Preliminary results
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indicate it can activate the CRC at nanomolar concentrations. A possible mechanism
by which the HCTL may react with the CRC is through lysine residues on the RyR
which may form alpha-amino carbon-centered radicals28 as shown in Figure 6.

Figure 6: HCTL, an activated carbonyl, conjugates readily to
lysine residues of proteins.
It is widely accepted that a majority of protein backbone cleavage and related damage
occurs via alpha-carbon radicals of amino acid residues. It has also been shown that
cysteinyl residues and glutathione may aid the formation of alpha-carbon radicals on
protein residues29. Other possibilities include the α-amino group of HCTL reacting
with aldehydes on the protein. It has been shown that the rate constant of HCTL
reacting with streptomycin occurs with a half life of 10 minutes which is 400 times
faster than the rate at which it reacts with lysine30. Other possibilities of HCTL
interaction are the oxidation of critical thiols or the homocysteinylation of the RyR
protein.
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Chapter 2: Materials and Methods

2.1 Materials
Tritium labeled ryanodine ([3H]-ryanodine) was purchased from PerkinElmer Life &
Analytical Sciences, Boston Massachusetts and stored in the freezer at -18˚C.
Unlabeled ryanodine was purchased from AgriSystems International, Wind Gap,
Pennsylvania. A stock solution was prepared at 10mM in 50% Methanol/deionized
distilled nanopure water. White New Zealand rabbits were purchased from Western
Oregon Rabbit Company, Philomath, Oregon. Ketamine HCl and Acepromazine
Maleate was purchased from the veterinary pharmacy at Oregon Health and Science
University, Portland, Oregon. Sheep hearts were a gift from Dr. Kent Thornburg,
Heart Research Center, Oregon Health and Science University, Portland, Oregon.
Ethylene glycol tetraacetic acid (EGTA) was purchased from Research Organics,
Cleveland, Ohio, and prepared in deionized distilled nanopure water and stored at
room temperature. CytoScint scintillation fluid was purchased from MP Biomedicals,
Costa Mesa, California. Homocysteine Thiolactone (HCTL) was a gift from Dr.
Robert M. Strongin, Department of Chemistry, Portland State University, Portland,
Oregon. HTLC stock solution was freshly prepared at less than 30µM in buffer
containing 250mM KCl, 15mM NaCl, and 20mM Piperazine-1,4-bis(2-ethanesulfonic
Acid (PIPES) set to pH 7.1 with KOH unless otherwise noted. Ranolazine was a gift
from Dr. Guy Salama, Department of Cell Biology and Physiology, University of
Pittsburgh, Pittsburgh, Pennsylvania. A Ranolazine stock solution was freshly
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prepared with 95% ethanol, which was purchased along with all other chemicals not
listed above from Sigma Aldrich, St. Louis, Missouri. Glutathione in both its oxidized
and reduced form was prepared on ice in ice cold deionized distilled nanopure water
containing 10µM EGTA at a concentration of 0.5M. Once the pH was adjusted to pH
7.0, aliquots were frozen in liquid N2.

2.2 Skeletal SR Preparation
Skeletal muscle SR vesicles were isolated from the fast twitch muscle of a 2-3 kg
White New Zealand male rabbit based on the method of MacLennan.31 Euthanizing
solution consisting of 58.8mg/ml Ketamine, 5.88mg/ml Xylazine, and 1.18mg/ml
Acepromazine Maleate was subcutaneously injected at a dose of 0.5ml/kg. Rabbit’s
jugular vein was cut and muscle was removed from the back and hind legs. After
removing the fat and connective tissue, muscles was minced and placed in a buffer
containing 120mM NaCl, 10mM Imidazole, 100µM Dithiothreitol (DTT), 100µM
EGTA, 0.1mM phenylmethanesulfonyl-fluoride (PMSF), 0.2µg/ml leupeptin, and 1 tablet
per 500ml of EDTA free SigmaFAST protease Inhibitor Cocktail tablets (Skeletal
Buffer A). Muscle was then blended for three cycles at a low speed for 15 seconds,
high speed for 60 seconds, followed by a 30 second rest period. The resulting solution
was centrifuged in a large Fiberlite rotor at 1600 x g for 10 minutes at 4˚C to remove
cell debris. The supernatant was then filtered through four layers of cheesecloth and
adjusted to pH7.4 with dry Imidazole. The filtrate was then spun in a Type 19 rotor at
10,000 x g for 15 minutes at 4˚C. The brown pellet composed of mitochondria was
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discarded and the supernatant was then filtered through four layers of cheesecloth. The
filtrate was then spun at 50,000 x g for 70 minutes at 4˚C. The resultant pellet which
consists of SR and myosin was then homogenized in 120mM NaCl, 10mM Imidazole,
100µM DTT, 50µM EGTA, 0.2µg/ml leupeptin, and 1 tablet per 500ml of EDTA free
SigmaFAST protease Inhibitor Cocktail tablets (Skeletal Buffer B). The solution was
then spun at 7,500 x g in a Ti-60 rotor for 10 minutes at 4˚C. The resulting myosin
pellet was discarded and the spin was repeated. The final supernatant, after removing
the second myosin pellet was then spun at 123,000 x g for 30 minutes at 4˚C which
resulted in a SR pellet. That pellet was homogenized in a buffer containing 100mM
KCl, 20mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.0
(KOH). Once the protein concentration was determined, and diluted, if needed, to
approximately 20mg/ml, the crude skeletal SR aliquots were stored in liquid N2 until
needed.

2.3 Cardiac SR Preparation
Cardiac SR vesicles were isolated from Sheep hearts obtained from OHSU based on
the method of Meissner and Henderson.32 Once the heart was removed from the sheep,
it was immersed in ice cold buffer containing 300mM Sucrose, 10mM PIPES, 0.5mM
PMSF, 1µg/ml Leupeptin at pH 7.4 with KOH (Cardiac Buffer A). The atria and other
connective and fatty tissue were removed and the remaining ventricles were minced
into small pieces to be blended at high speed in a waring blender for 20 seconds. After
a 30 second rest period the solution was blended again on high for 20 seconds. The
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resultant solution was centrifuged at 9,000 x g in the large fiberlite rotor at 4˚C. The
supernatant was then filtered through two layers of cheesecloth and spun at 44,000 x g
for 75 minutes in a type 19 rotor at 4˚C. The resultant pellet was homogenized in
Cardiac Buffer A and spun at 25,000 x g for 30 minutes at 4˚C. The resulting SR pellet
was homogenized in a buffer containing 100 mM Sucrose, 5 mM HEPES at pH 7.2
(Tris-base). Once protein concentration was determined, and diluted if needed to
approximately 20mg/ml, the crude cardiac SR aliquots were stored in liquid N2.

2.4 Protein Determination
Protein concentrations of the SR were determined by the method of Kalckar33. The
absorbance peak at 280nm is mainly due to the presence of tyrosine and tryptophan
and the peak at 230nm is mainly due to the peptide bond of the protein backbone.
Using this information, absorption was measured on an Agilent 8453 UV-Visible
photodiode array spectrophotometer at 230nm and 280nm . Data was also collected at
260nm in order to correct for nucleic acids using the following equations.

[SR]mg/ml = 1.45 x Abs280 – 0.74 x Abs260

(Equation 1)

[SR]mg/ml = 0.185 x Abs230 – 0.748 x Abs260

(Equation 2)

The process was repeated twice, and the average protein concentration was calculated.
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2.5 Equilibrium Ryanodine Binding Assay
The molecule ryanodine binds with nanomolar affinity to a single class of proteins
near the junctional region of the SR34 under certain conditions. With a few exceptions,
such as silver, CRC activators stimulate ryanodine binding, whereas compounds that
inhibit the CRC, inhibit binding. Tritium labeled ryanodine ([3H]-ryanodine) binding
assays were carried out at a [3H]ryanodine concentration of 1nM, and 14nM unlabeled
ryanodine for skeletal SR, and a [3H]ryanodine concentration of 2nM, and 13nM
unlabeled ryanodine for cardiac SR. SR vesicles (0.5mg/ml) were incubated in a
buffer containing 250mM KCl, 15mM NaCl, and 20mM Piperazine-1,4-bis(2ethanesulfonic Acid (PIPES), pH 6.8, 7.1 or 7.4 as dictated by each experiment, at 37˚
Celsius for 3 hours in order for binding to reach equilibrium. Samples were then
quenched by rapid filtration through Whatman glass fiber filters using a Brandel cell
harvester. Filters were washed twice with approximately 4ml of buffer containing
250mM KCl, 15mM NaCl, 20mM tris-(hydroxymethyl)- aminomethane (TRIS), and
100µM CaCl2 at pH 7.1 (HCl). These filters were then dried in an oven at 50˚C for
two hours then incubated with agitation in 3ml of CytoScint scintillation fluid for one
hour. Radioactivity was counted by a Beckman LS 6000 scintillation counter with an
efficiency of approximately 55%. Nonspecific binding was measured in the presence
of 200nM unlabeled ryanodine, and 4mM ethylene glycol tetra acetic acid (EGTA).
Total specific activity was determined by adding an extra aliquot of experimental
[3H]-ryanodine buffer solution to scintillation fluid and counting the sample.
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2.6 Initial Rate Ryanodine Binding Assay
Binding kinetics were determined in a similar manner to equilibrium Ryanodine
binding experiments described above with small modifications. When working with
skeletal SR vesicles the addition of 1nM [3H]-ryanodine occurred over four time
points, three minutes apart before being quenched with rapid filtration. When working
with cardiac SR vesicles the addition of 4nM [3H]-ryanodine occurred over four time
points, five minutes apart before being quenched with rapid filtration.

2.7 Hill Analysis
Calcium dependent ryanodine binding measurements were fit to the Hill equation.

B = Bmax

[ x ]n
k d + [ x]n

(Equation 3)

Where Bmax is the maximum binding, [x] is the free Ca2+ concentration determined
with the computer program “Bound and Determined”, kd is the dissociation constant of
the binding site and n is the Hill coefficient. The graphing software SigmaPlot was
used to determine the best fit parameters for the half maximal binding concentration
(EC50) which was calculated by equation 4.

EC50 = k

1
 
n
d

(Equation 4)
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2.8 Redox Potential
To study the effects of channel modulators in more reduced or oxidized environments
it is possible to mimic the cellular redox status by using various concentrations of
GSH and GSSG determined by the following equation.

E solution = E ° + 2.3

RT
RT
[GSSG ]
(7.0 − pH actual ) + 2.3
log
F
nF
[GSH ]2

(Equation 5)

Where Esolution is the redox potential of the solution, E˚ is the standard potential of
glutathione (-0.24V), pHactual is the pH of the buffer, R is the gas constant (8.31 deg-1
mol-1), T is the absolute temperature (K), n is the number of electrons transferred (n
=2 for glutathione) and F is the Faraday constant (96406 J/V).

2.9 Redox titrations
SR vesicles were incubated at various solution redox potentials and channel modifiers
for 1 hr at 37˚C before measurement of the initial rate of ryanodine binding assay was
started with the addition [3H]ryanodine. Values for the maximum initial rate of
Ryanodine binding, Bmax, were obtained from each individual redox titration at its
most oxidized point, and the minimum initial rate of Ryanodine binding, Bmin, was
obtained from its most reduced point. With these values Equation 6 was used to plot
Esolution as a function of the initial rate of Ryanodine binding, Bʹ, resulting in a curve
in which the x intercept determines the redox potential of the RyR, ERyR.


2.3




 



  

 

(Equation 6)
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Chapter 3: Results

3.1 Ca2+ dependence of Cardiac and Skeletal SR at various pH and redox potentials.
The Ryanodine Receptors found in cardiac muscle have different sensitivities to
activators and inhibitors than those that are found in skeletal muscle. This variation in
response is unlikely due to the difference in species as it has been reported that
preparations from diverse species such as mouse, rabbit, and sheep exhibit similar
trends, especially with respect to Ca2+ sensitivity35. It has also been shown previously
that Ryanodine Binding is affected by pH36,37,38 with optimal binding between pH 7.2
and pH 7.8 39. Figure 7 shows that ryanodine binding to rabbit skeletal muscle SR
reaches a maximum between 30-100µM free Ca2+ at pH 7.4 and between 3-10 µM
free Ca2+ at pH 6.8 after a gradual increase in binding. Sheep cardiac muscle SR has a
sharper response to Ca2+ than skeletal muscle SR showing a higher degree of
cooperativity and reaches maximum binding between 300-700nM free Ca2+ at pH 7.4
and a maximum binding between 700nm-3 µM free Ca2+ at pH 6.8. There is also
significantly higher binding of ryanodine to skeletal muscle SR at pH 7.4 than to
cardiac muscle SR. At pH 6.8 there is little difference observed in maximal ryanodine
binding to skeletal vs. cardiac muscle SR. Although there are differences in the Ca2+
dependence of ryanodine binding at pH 7.4 vs. pH 6.8, large changes in maximal
binding between skeletal and cardiac SR are only observed at pH 7.4.
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Ca

2+

dependence of ryanodine binding in skeletal and cardiac muscle at pH 6.8 and pH 7.4
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Figure 7: Ca2+ dependent ryanodine binding as a function of pH in skeletal and
cardiac muscle SR. Skeletal muscle SR at pH 7.4 (●), pH 6.8 (■). Cardiac
muscle SR at pH 7.4 (♦), pH 6.8 (▼).

The oxidation state of the cysteine residues on the cytoplasmic domain of the RyR
have been shown to be important in determining the calcium sensitivity of the RyR40.
Shown in Figures 8 and 9, and summarized in Table 1, are the effects of two different
redox potentials on Ca2+ dependent ryanodine binding to skeletal muscle SR.
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Effects of Redox Solution Potential on Ca2+
dependence of ryanodine binding
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Figure 8: Shift in Ca2+
dependent ryanodine
binding due to solution
redox potential at pH
7.4. Control Skeletal
muscle SR at pH 7.4 (●);
-90mV solution redox
potential (■); -200mV
solution redox potential
(▼).
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Figure 9: Shift in Ca2+
dependent ryanodine
binding due to solution
redox potential at pH
6.8. Control Skeletal SR
at pH 6.8 (●); -90mV
solution redox potential
(■); -200mV solution
redox potential (▼).
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kd at pH 6.8
(µM)
kd at pH 7.4
(µM)
Maximal
ryanodine binding
at pH 6.8
(pmol/mg)
Maximal
ryanodine binding
at pH 7.4
(pmol/mg)

Skeletal
Muscle SR
Control
0.8±0.1

Skeletal
Muscle SR
-200mV

Skeletal
Muscle SR
-90mV

2.5±0.3

0.5±0.1

Cardiac
Muscle SR
Control
0.9±0.1

0.4±0.1

0.4±0.1

0.3±0.1

0.1±0.1

1.0

0.8

1.2

0.9

2.3

1.5

2.7

1.1

Table 1: Shift in kd Ca2+ and maximum binding due to pH and solution redox potential.

As summarized in Table 1 at both pH 6.8 and pH 7.4, a more oxidizing solution redox
potential increases maximal ryanodine binding. At pH 7.4 sensitivity of the RyR1 to
activation by lower Ca2+ concentrations is increased.

3.2 Shift in Redox Potential of the RyR as a function of pH
It has previously been shown that the ryanodine receptor acts as a redox sensor35.
Channel activators shift the redox potential of the receptor to a more negative or
reduced value. This results in the oxidation of critical thiols to disulfides. In contrast
channel inhibitors shift the redox potential of the receptor to a more positive, or more
oxidized potential resulting in the reduction of disulfide bonds and a decrease in the
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rate of ryanodine binding. Figure 10 & Figure 11 show redox titrations at three
different pH values and demonstrates that at lower pH thiols require stronger oxidizing
conditions to activate the channel. This shift in value is expected as the –S- form is
more easily oxidized than the –SH form. The ERyR values for each titration are
summarized in Table 2.

pH 6.8

pH 7.1

pH 7.4

Skeletal Muscle SR

-88mV

-133mV

-155mV

Cardiac Muscle SR

-141mV

-217mV

-236mV

Table 2: ERyR values for skeletal muscle SR and cardiac muscle SR redox titration as
a function of pH.

Inital rate of Ryanodine Binding (fmol/mg/min)

Redox titrations as a function of pH
(Skeletal Muscle)
18

Figure 10: Shift of redox
potential titration as a function
of pH in skeletal muscle SR.
pH 6.8 (●),
pH 7.1 (▼), pH 7.4 (■). All
experiments are carried out
with 50µM free Ca2+.
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2
-220

-200

-180

-160

-140

-120
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Inital rate of Ryanodine Binding (fmol/mg/min)
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Figure 11: Shift of redox
potential titration as a function
of pH in cardiac muscle SR.
pH 6.8 (●), pH 7.1 (▼), pH
7.4 (■). All experiments are
carried out with 50µM free
Ca2+.

Redox titrations as a function of pH
(Cardiac Muscle)
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3.4 Change in Ca2+ dependent ryanodine binding due to the drug Ranolazine
Conditions that are associated with increased channel open probabilities in single
channel artificial lipid bilayer experiments are usually associated with increases in 3HRyanodine binding measurements. Ranolazine is one of the exceptions. No effect on
Ryanodine binding was seen in cardiac or skeletal muscle as a function of increasing
concentration of Ranolazine, however at the single channel level an inhibition with a
kd of 10 ± 3 µM in cardiac SR vesicles (Yanping Ye ~ unpublished data) was shown.
As the therapeutic effects of Ranolazine are due to decreasing intracellular Ca2+ load
the effects of 30µM Ranolazine in cardiac SR were studied and a shift in the Ca2+
dependence of Ryanodine binding was observed at both pH7.1, where the kd shifted
from 0.49µM ± 0.02 to 0.66µM ± 0.03 and at pH 7.4 where the kd shifted from
0.03µM ± 0.01 to 0.04µM ± 0.01 as shown in Figure 12.
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Figure 12: Ca2+ dependent ryanodine binding in cardiac muscle SR with and
without 30µM Ranolazine. Control at pH 7.1 (black sphere ●); +30µM Ranolazine
at pH 7.1 (black triangle ▲); control at pH 7.4 (red sphere ●); +30µM Ranolazine
at pH 7.4 (red triangle▲).

3.5 Ca2+ dependence of Homocysteine Thiolactone
Homocysteine thiolactone like ranolazine does not affect maximal 3H-Ryanodine
binding measurements over the range of concentrations that it is soluble. HCTL has
shown to shift Ca2+ dependent ryanodine binding in cardiac muscle SR from a kd of
73.5nM ± 1.8 to a kd of 43.2nM ± 2.3 at 100nM when the solution potential has been
set to -210mV and pH 7.4 as shown in Figure 13.
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Effects of 100nM HCTL on Ca2+ dependent ryanodine binding in
Cardiac SR at pH 7.4 with and without a reducing solution potential
1.6

Ryanodine Bound (pmol/mg)

1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0

0.000

0.050

0.100

Free Ca

2+

0.150

0.200

0.250

in solution (µM)

Figure 13: Shift in Ca2+ dependent ryanodine binding in cardiac muscle due to 100nM
HCTL. Control cardiac muscle SR at pH 7.4 and -210mV (●); +100nM
HCTL at -210mV (▼); Control cardiac SR at pH 7.4 without redox
potential set (■) +100nM HCTL without redox potential set (♦)
At other concentrations of HCTL, 1nM, 10nM, 1µM the kd of the Ca2+ dependence
was within two standard deviations of the control as shown in Figure 14 and
summarized in Table 3.

kd (nM)

Control

10nM HCTL

100nM HCTL

1µM HCTL

73.5±1.8

69.6±1.3

42.1±2.4

70.8±8.6

Table 3: Shift in Ca2+ dependent ryanodine binding kd as a function of HCTL
concentrations
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2+
Effects of HCTL on Ca dependent ryanodine binding in cardiac muscle SR at pH 7.4

1.2

Ryanodine Bound (pmol/mg)

1.0

0.8

0.6

0.4

0.2

0.0

0.00
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2+

Free Ca in solution (µM)

Figure 14: Shift in Ca2+ dependent ryanodine binding as a function of HCTL
concentration in cardiac muscle SR. Control Cardiac SR at pH 7.4 (●)
+10nM HCTL (▼) +100nM HCTL (■) +1µM HCTL (♦). All experiments
aer carried out at -210mV solution redox potential.

Skeletal muscle does not exhibit the biphasic effect of HCTL, however it does seem to
have a effect on cooperativity, as the hill number generated from the fit of the 1µM
addition of HCTL on Ca2+ dependent ryanodine binding is much less. Shifts in Ca2+
dependence is seen in Figure 15 and summarized in Table 4 with the largest shift
occurring at 1µM HCTL.

kd (µM)

Control

10nM HCTL

100nM HCTL

1µM HCTL

0.393±0.077

0.289±0.054

0.338±0.067

0.872±0.255

Table 4: Shift in Ca2+ dependence kd in skeletal muscle SR due to various
concentrations of HCTL
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Effects of HCTL on Ca2+ dependent ryanodine binding in
skeletal muscle SR at pH 7.4

Figure 15: Shift in Ca2+ dependent ryanodine binding in skeletal muscle SR due to
HCTL. Control skeletal SR at pH 7.4 (●); +10nM HCTL (▼)
+100nM HCTL (♦) +1µM HCTL (▲)

27

Chapter 4: Conclusions

The effects of Ca2+ dependent activation is of major importance in the study of RyR
since other channel modifiers cannot effect the channel in the absence of Ca2+, or they
require Ca2+ for maximum activation. In this study of the high-affinity Ca2+ binding
site, both an increase in pH and a more oxidative solution redox status increased
binding as well as changed the amount of Ca2+ required for channel activation in both
skeletal and cardiac muscle SR. These observation are in agreement with the
previously reported conclusions that during muscle fatigue and a decrease in pH,
higher concentrations of Ca2+ are required to stimulate contraction.

Activation by an oxidative solution redox potential follow similar trends in both
cardiac and skeletal muscle SR. At higher pH the ERyR values shift to the left, or a
more reduced potential, while with the addition of an inhibitor, the ERyR value shifts to
the right, or a more oxidizing potential. While the trends are similar the actual values
of the ERyR2 values are significantly more negative than the values that are found from
skeletal muscle SR which is a possible explanation for why the RyR2 is much more
easily oxidized than the RyR1.

In skeletal muscle SR lower Ca2+ concentrations shift the redox potential to a more
positive potential, as opposed to cardiac muscle SR where when the free Ca2+
concentrations drop below 30µM there ceases to be an activation even at very
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oxidized redox solution potentials. Preliminary data shows that the cardiac receptor
activity can be modulated by redox potential only when there is a free Ca2+
concentration between 30µM to 1mM. This is outside the range of physiological Ca2+
concentrations in the heart and raises questions about the role of redox potential as a
modulator of RyR2. Although oxidative stress is a critical challenge to the SR’s ability
to control Ca2+ homeostasis in the heart at this point it is not clear what role, if any, the
redox potential plays in altering function of RyR2.

Ranolazine desensitized the cardiac channel to activate by calcium which should lead
to higher concentrations of Ca2+ being required to activate the channel under
physiological conditions. During heart failure and arrhythmias it is known that the
cellular Ca2+ concentration is elevated, ranolazine’s ability to desensitize the receptor
to activation by Ca2+ should be beneficial towards maintaining calcium homeostasis
under these conditions. It should prevent or decrease premature release of Ca2+ from
the SR (arrhythmias).

Both Ranolazine and HCTL altered the Ca2+ dependence of ryanodine binding
without effecting the maximum amount of binding. Surprisingly, the effect of HCTL
was observed only in a reduced solution potential which leads us to speculate that the
RyR’s response to HCTL is caused by an interaction with sulfhydryl groups on the
protein being in a reduced state. The mechanism underlying this interaction is still
under investigation.
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